Gilead Sciences, Inc. (GILD) Stock: Price, Forecast & Analyst Target

Gilead Sciences, Inc. Company Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc.

Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for unmet medical needs. The company's portfolio includes treatments for HIV/AIDS, liver diseases, oncology, and other life-threatening conditions.

Key Facts

• Sector: Healthcare
• Industry: Drug Manufacturers - General
• Headquarters: Foster City, CA, US
• CEO: Daniel O'Day
• Employees: 17600

What Gilead Sciences, Inc. Does

Develops and commercializes antiviral drugs for HIV/AIDS.,Offers treatments for liver diseases, including hepatitis B and C.,Provides cell therapies for certain types of cancer.,Researches and develops new therapies for life-threatening diseases.,Collaborates with other companies to expand its pipeline.,Markets its products globally, including in the United States and Europe.,Focuses on areas of unmet medical need.

Business Model

Develops and patents pharmaceutical products.,Conducts clinical trials to demonstrate safety and efficacy.,Obtains regulatory approvals from agencies like the FDA.,Manufactures and distributes its products globally.,Generates revenue through sales of its patented drugs.

Key Competitors

Merck & Co., Inc., Amgen Inc., Novo Nordisk A/S, Pfizer Inc., Danaher Corporation

GILD Investment Analysis

Investment Thesis

Gilead Sciences, Inc. presents a compelling investment case based on its established dominance in HIV treatment, expanding oncology portfolio, and strategic collaborations. With a P/E ratio of 17.70 and a profit margin of 31.0%, Gilead demonstrates financial stability. Growth catalysts include pipeline advancements in oncology and continued revenue from HIV therapies. A dividend yield of 2.43% offers income potential. However, potential risks include patent expirations on key drugs and competition from other pharmaceutical companies. Investors should monitor the progress of Gilead's pipeline and its ability to maintain market share in key therapeutic areas.

Growth Catalysts

• Upcoming: Clinical trial results for new oncology drug candidates.
• Ongoing: Continued revenue growth from Biktarvy in HIV treatment.
• Ongoing: Expansion of cell therapy business through new indications for Yescarta and Tecartus.
• Upcoming: Regulatory approvals for new therapies in development.

Risk Factors

• Potential: Patent expirations on key drugs, leading to generic competition.
• Ongoing: Competition from other pharmaceutical companies in key therapeutic areas.
• Potential: Pricing pressures from government and payers.
• Potential: Clinical trial failures.

Questions & Answers

Is GILD a good stock to buy?

Whether GILD is a suitable investment depends on your goals, risk tolerance, and time horizon. Evaluate Gilead Sciences, Inc.'s revenue growth, profit margins, debt levels, and valuation relative to peers. This is not financial advice—consult a qualified advisor before investing.

What is the GILD MoonshotScore?

The MoonshotScore rates GILD from 0 to 100 across growth potential, financial health, market momentum, and risk factors. It is updated as market data refreshes. This score is informational only—not a buy or sell recommendation.

How often is GILD data updated?

GILD's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update as market data refreshes.

What are the risks of investing in GILD?

Risk categories for GILD include market risk, company-specific risk, financial risk (debt, cash burn), and macroeconomic risk. Review the Risk Factors section for details specific to this stock. All investments carry risk of loss.